EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extramedullary AML: Clinical and Molecular Features

Yael Morgenstern iD, Claire Andrews, Eshetu G Atenafu iD, Steven Chan, Vikas Gupta, Mark D Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen Yee iD, Hassan Sibai iD

Cancers · 24.04.2026 · 18 (9) · 1362

DOI: 10.3390/cancers18091362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.04.2026. Verfasst von Yael Morgenstern und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia with extramedullary disease (EMD-AML) represents a distinct clinical entity associated with diagnostic and therapeutic challenges, and its prognostic significance remains uncertain.

Methods

A retrospective study of 617 adults with newly diagnosed AML (2005–2018) was conducted, analyzing 246 patients with EMD-AML and 371 without EMD involvement. The clinical characteristics and treatment outcomes were analyzed. Propensity score matching (PSM) was applied to adjust for baseline confounders.

Results

Patients with isolated EMD-AML and those with concurrent bone marrow involvement had comparable clinical outcomes. NPM1 mutations (48% vs. 25%, p = 0.0002) and t(8;21) translocation (23.2% vs. 3.7%, p < 0.001) were enriched in the EMD-AML cohort. After PSM, EMD-AML patients achieved a higher overall response rate compared with non-EMD-AML (88.1% vs. 72.0%, p = 0.0002) but experienced significantly higher relapse rates (35.7% vs. 15.5%, p < 0.0001). Despite the achievement of a higher response rate, EMD-AML was associated with shorter median overall survival (OS) (14.2 vs. 64.1 months, p < 0.0001) and event-free survival (EFS) (9.5 vs. 55.9 months, p < 0.0001). In a multivariable analysis, EMD-AML remained independently associated with worse OS and EFS (OS HR 1.79, p = 0.01; EFS HR 1.95, p = 0.001). Allogeneic hematopoietic stem cell transplantation did not confer a survival advantage in EMD-AML patients.

Conclusions

EMD-AML, whether isolated or concurrent with bone marrow disease, represents a high-risk entity characterized by poor long-term outcomes despite strong initial response rates. Obtaining tissue biopsies for molecular profiling may help improve risk stratification, identify targetable mutations and guide individualized treatment.

Schlagwörter

Stichwörter der Autor:innen

AMLextra meduallary AMLleukemiamyeloid sarcoma

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
  • Department of Biostatistics, University Health Network, Toronto, ON M5G 1X6, Canada.
  • Division of Biostatistics, University of Toronto, Toronto, ON M5S 3E3, Canada.
  • Department of Medicine, Division of Hematology, University of Toronto, Toronto, ON M5S 3H2, Canada.

ORCID-Profile: Yael Morgenstern, Eshetu G Atenafu, Karen Yee, Hassan Sibai

Zitieren

APA

Morgenstern, Y., Andrews, C., Atenafu, E. G., Chan, S., Gupta, V., Minden, M. D., Maze, D., Schimmer, A., Schuh, A., Yee, K., & Sibai, H. (2026). Extramedullary AML: Clinical and Molecular Features. Cancers, 18(9), 1362. https://doi.org/10.3390/cancers18091362

Vancouver

Morgenstern Y, Andrews C, Atenafu EG, Chan S, Gupta V, Minden MD, et al. Extramedullary AML: Clinical and Molecular Features. Cancers. 2026;18(9):1362. doi:10.3390/cancers18091362

BibTeX
@article{Morgenstern2026,
  author = {Morgenstern, Yael and Andrews, Claire and Atenafu, Eshetu G and Chan, Steven and Gupta, Vikas and Minden, Mark D and Maze, Dawn and Schimmer, Aaron and Schuh, Andre and Yee, Karen and Sibai, Hassan},
  title = {Extramedullary AML: Clinical and Molecular Features},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1362},
  doi = {10.3390/cancers18091362}
}
Kostenlos starten →